Palbociclib, ribociclib, and abemaciclib, the three approved CDK4/6 inhibitors, are established first-line treatment options for HR+/HER2− advanced or metastatic breast cancer (a/mBC). Yet no randomized, head-to-head trial has compared the three agents directly. In the absence of head-to-head randomized trials, clinicians, payers, and health technology assessment (HTA) bodies increasingly rely on real-world evidence (RWE) to compare outcomes across agents.
A team from EVERSANA’s Value & Evidence (Sofiya Portuhay, Elizabeth M. Salvo-Halloran, Imtiaz A. Samjoo), together with academic and industry collaborators, conducted a systematic literature review (SLR) that identified 32 comparative real-world studies and appraised their methodological quality using three validated assessment frameworks.
KEY FINDING
Among 21 full-text studies, only 7 used propensity-based methods to balance treatment groups. Eight relied on multivariable adjustment alone, and 6 reported entirely unadjusted comparisons despite important baseline imbalances between treatment groups.
A Larger Evidence Base Does Not Equal Better Outcomes
Across the majority of included studies, real-world progression-free survival and overall survival were broadly comparable between the three CDK4/6 inhibitors. Palbociclib accounted for the largest patient population and the longest follow-up, reflecting earlier approval and use than its competitors. This greater data maturity confers no evidence of superior clinical performance.
Interpreting Comparative RWE with Caution
A handful of individual studies did report statistically significant advantages but were often limited by smaller sample sizes, shorter follow-up periods, or inadequate adjustment for confounding. In several cases, apparent advantages diminished as longer-term follow-up became available.
Most full-text studies clearly reported their objectives, data sources, and outcome definitions. However, transparent reporting does not necessarily reduce risk of bias. Many analyses were vulnerable to confounding due to differences in patient characteristics such as age, performance status, menopausal status, and disease burden. Because these factors can influence outcomes independently of treatment selection, the methods used to adjust for baseline imbalances are critical when interpreting comparative RWE.
Implications for Decision-Makers
For clinicians, payers, and HTA bodies, the message is one of measured caution: the current real-world literature should not be read as demonstrating meaningful differences in effectiveness among palbociclib, ribociclib, and abemaciclib in first-line HR+/HER2− a/mBC. Quality assessment, not just the direction of an effect estimate, must be part of how comparative RWE is interpreted. Looking ahead, the review calls for real-world studies that consistently apply robust, propensity-based adjustment; standardize how outcomes are defined and measured across data sources; extend follow-up for more recently approved agents; and broaden geographic representation beyond the North American and Western European settings that dominate the evidence base today.
Author
As Vice President of the Value & Evidence team at EVERSANA®, Imtiaz leads evidence synthesis projects that support global HEOR initiatives involving systematic literature reviews, indirect treatment comparisons, and health economic modelling, to support reimbursement and market access for pharmaceuticals. Imtiaz…
Sofiya joined the Value & Evidence division of EVERSANA in 2021 as a Research Assistant and currently holds the position of Associate Manager. At EVERSANA, Sofiya has supported a multitude of systematic and targeted…
As a director on the Value & Evidence team at EVERSANA®, Elizabeth leads evidence synthesis projects involving systematic literature reviews and indirect treatment comparisons, supporting reimbursement and market access of pharmaceutical products. Elizabeth specializes…
Emma joined the Value & Evidence team at EVERSANA in 2023 as a Research Associate. During her time at EVERSANA, Emma has contributed to systematic and targeted literature reviews, manuscript development, economic modelling, and…